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In Brief
NPC1 disease is a neurodegenerative
disorder that occurs due to mutations in
the lysosomal NPC1 cholesterol
transporter. Vivas et al. define steps in the
pathogenic cascade, downstream of
lysosomal cholesterol accumulation, that
lead to hyperexcitability in NPC1 disease
neurons.
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SUMMARY

There is increasing evidence that the lysosome is
involved in the pathogenesis of a variety of neurodegenerative disorders. Thus, mechanisms that link
lysosome dysfunction to the disruption of neuronal
homeostasis offer opportunities to understand the
molecular underpinnings of neurodegeneration and
potentially identify specific therapeutic targets.
Here, using a monogenic neurodegenerative disorder, NPC1 disease, we demonstrate that reduced
cholesterol efflux from lysosomes aberrantly modifies neuronal firing patterns. The molecular mechanism linking alterations in lysosomal cholesterol
egress to intrinsic tuning of neuronal excitability is
a transcriptionally mediated upregulation of the
ABCA1 transporter, whose PtdIns(4,5)P2-floppase
activity decreases plasma membrane PtdIns(4,5)P2.
The consequence of reduced PtdIns(4,5)P2 is a parallel decrease in a key regulator of neuronal excitability, the voltage-gated KCNQ2/3 potassium channel, which leads to hyperexcitability in NPC1 disease
neurons. Thus, cholesterol efflux from lysosomes
regulates PtdIns(4,5)P2 to shape the electrical and
functional identity of the plasma membrane of neurons in health and disease.
INTRODUCTION
Neurodegeneration is a common feature of many neurological
disorders. Cell biological, genetic, and in vivo work increasingly
emphasizes the crucial role that lysosomes play in neurodegeneration. Once simply thought of as acidic centers for degradation
and recycling, lysosomes are now known to be highly dynamic
signaling organelles that can mediate signal transduction via
the mammalian target of rapamycin complex 1 (mTORC1) and
regulate gene expression via transcription factor EB (TFEB)
and other transcription factors (Laplante and Sabatini, 2012).
These pathways are particularly relevant for maintaining brain
homeostasis, as dysfunction of the endolysosomal and auto-

phagic pathways has been associated with common neurodegenerative diseases, such as Alzheimer and Parkinson (Fraldi
et al., 2016; Laplante and Sabatini, 2012), and lysosomal storage
disorders—a group of inherited disorders characterized by
the intralysosomal buildup of partially degraded metabolites,
including cholesterol (Castellano et al., 2017; Schulze and
Sandhoff, 2011).
Increasingly, dysregulation of cholesterol homeostasis is proposed as a contributing factor in the development of neurodegenerative disorders (Abdel-Khalik et al., 2017; Chang et al.,
2017; Di Paolo and Kim, 2011; Eriksson et al., 2017). A main
source of neuronal cholesterol is the internalization of cholesterol that is synthesized by glia. This import of cholesterol is
predominantly mediated by astrocyte-derived apolipoprotein
E (ApoE)-containing lipoprotein particles (Boyles et al., 1989;
Herz and Bock, 2002). These lipoproteins are internalized via
clathrin-mediated endocytosis and delivered to late lysosomal
compartments where acidic lipases liberate cholesterol. The
free cholesterol is transferred by the luminal Niemann-Pick C2
protein to the membrane-bound Niemann-Pick type C1
(NPC1) protein for export to the endoplasmic reticulum (ER) by
sterol transfer proteins (e.g., ORP5, ORPL1) at membrane contact sites between the ER and the lysosome (Du et al., 2011;
Karten et al., 2009; Li et al., 2016; Luo et al., 2017; Zhao and
Ridgway, 2017). The importance of the NPC1 protein in regulating the transfer of cholesterol to the ER is underscored
by the severity of the fatal Niemann-Pick type C1 (NPC1) neurodegenerative disease. This autosomal recessive lysosomal
storage disorder most commonly occurs due to a single
I1061T substitution that results in misfolding of the NPC1 protein
and subsequent targeting for ER-associated degradation (Gelsthorpe et al., 2008). The reduction in functional NPC1 protein
results in massive luminal accumulation of cholesterol in lysosomes and cellular changes in cholesterol homeostasis (Millard
et al., 2000). Neurologically, NPC1 patients typically exhibit progressive impairment of motor and intellectual function, before
succumbing to the disease, tragically within the first 2 decades
of life (Vanier, 1999). Despite the commonality of altered cholesterol metabolism and compromised neuronal function in neurodegenerative disorders, the molecular mechanisms that link
cellular changes in cholesterol with alterations in neuronal excitability are absent. Thus, this monogenetic disease, with such
profound alterations in cholesterol metabolism, allows us to
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Figure 1. Pharmacological Inhibition of NPC1 Increases Neuronal Excitability
(A) Schematic of the hypothesis: lysosomal cholesterol efflux regulates neuron excitability.
(B) Inverted confocal micrographs of healthy (left) and NPC1I1061T (right) fibroblasts fixed and stained with filipin. Insets show the accumulation of cholesterol
within the lysosome lumen.
(C) Comparison of normalized cumulative frequencies of vesicle size between healthy (black, 16 cells, 777 vesicles) and NPC1I1061T (red, 14 cells, 545 vesicles)
fibroblasts. *p < 0.0005, Mann-Whitney-Wilcoxon test.
(D) Inverted confocal micrographs of control (left) and U18-treated (right; 1 mM, 18 h) sympathetic neurons fixed and stained with filipin.
(E) Comparison of normalized cumulative frequencies of vesicle size between neurons cultured without (black, 17 cells, 2,186 vesicles) and with (red, 20 cells,
1,373 vesicles, *p < 0.0005, Mann-Whitney-Wilcoxon test) U18.
(F) Top: schematic of current injection protocol. Membrane potential was held at 65 mV, and current steps were given from 40 to 100 pA in 10-pA steps.
Center: voltage traces from control neuron. Bottom: voltage traces from U18-treated neuron. Note that the U18-treated neuron fires several APs with 40 pA
current injection (bottom, black trace, 9 APs) compared to a neuron cultured without U18 (middle, black trace, 1 AP). Dotted lines: 65 mV.
(G) Summary of Vrest measured from neurons cultured without (empty circles, n = 8) and with (red circles, n = 8) U18.
(H) Quantification of the amount of current required to fire at least 1 AP (rheobase) in control (empty circles, n = 8) and U18-treated (red circles, n = 8) neurons.
(I) Comparison of the number of APs induced with increasing current injections in control (empty circles, n = 8) and U18-treated (red circles, n = 8) neurons.
In all figures, average data are presented as mean ± SEM. See also Figure S1.

test the hypothesis that altered lysosomal cholesterol metabolism can change the intrinsic electrical excitability of neurons
(Figure 1A).
Neuronal excitability depends on the proper function of ion
channels whose activities can be tuned by plasma membrane (PM) lipids, including cholesterol and the minor phosphoi-

nositide, phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2).
PtdIns(4,5)P2 regulates upward of 100 ion channels and transporters (Hilgemann et al., 2001; Hille et al., 2015), while cholesterol commonly suppresses the activity of several types of channels, including inwardly rectifying K+ channels (Romanenko
et al., 2004), Ca2+-sensitive K+ channels (Bukiya et al., 2011;
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Crowley et al., 2003; Purcell et al., 2011), and voltage-gated K+
channels (Abi-Char et al., 2007; Hajdú et al., 2003). Despite
separate biosynthetic pathways, the metabolism of cholesterol
and phosphoinositides is not as distinct as previously thought.
The transport of cholesterol between intracellular membranes
at membrane contact sites uses phosphoinositides as the
driving force to transport cholesterol (Mesmin et al., 2013).
Another link between cholesterol and phosphoinositide metabolism involves the ABCA1 cholesterol transporter, which has
been reported as being a PtdIns(4,5)P2 floppase (exports
PtdIns(4,5)P2 out of the cell) (Gulshan et al., 2016). Hence, alterations in the cholesterol content of organelle membranes could
dysregulate ion channel activity directly or indirectly by modifying PtdIns(4,5)P2.
Here, we find that both pharmacological inhibition of NPC1 and
its genetic mutation in an established transgenic animal model of
the disease render neurons hyperexcitable. Furthermore, we
discover that reduced KCNQ2/3 current density underlies this
electrical hyperexcitability, which is mediated by a significant
reduction in the abundance of PM PtdIns(4,5)P2. The molecular
mechanism that leads to a reduction in PtdIns(4,5)P2 in NPC1 disease is a sterol regulatory element-binding protein (SREBP)dependent upregulation of ABCA1. These data support the hypothesis that the regulated efflux of cholesterol from lysosomal
membranes via NPC1 continually aids in the regulation of
neuronal excitability and reveals a link between lysosomal
cholesterol and phosphoinositide metabolism in NPC1 disease.
This link could have broad implications for other neurodegenerative disorders.
RESULTS
Pharmacological Inhibition of NPC1 Increases Neuronal
Excitability
NPC1 disease cells exhibit a characteristic accumulation of
cholesterol in lysosomes (Gelsthorpe et al., 2008; Millard et al.,
2000; Yu et al., 2005). This cellular phenotype has become useful
in the diagnosis of NPC1 disease since it is readily identifiable
following staining with the naturally fluorescent polyene antibiotic, filipin (Vanier and Latour, 2015). Figure 1B presents
confocal micrographs of filipin-stained fibroblasts isolated from
healthy and NPC1 patients carrying the most prevalent mutation
(NPC1I1061T) (Millat et al., 1999; Park et al., 2003). Analysis of
these images revealed that NPC1I1061T fibroblasts have larger
cholesterol-containing vesicles (Figure 1C), with the median
vesicle size of healthy fibroblasts being 0.22 mm2 (Q1 =
0.13 mm2 and Q3 = 0.39 mm2) and NPC1I1061T fibroblasts being
0.38 mm2 (Q1 = 0.18 mm2 and Q3 = 0.75 mm2). To mimic the
cholesterol accumulation phenotype of NPC1 disease in isolated
neurons, we used the well-characterized NPC1 inhibitor
U18666A (U18; 1 mM). This cationic amphiphile directly binds
to the sterol-sensing domain of the NPC1 protein (Lu et al.,
2015) and blocks the efflux of cholesterol from lysosomes (Lange
et al., 2000), thereby mimicking NPC1 disease. Cultured sympathetic (Figures 1D and 1E) or hippocampal (Figure S1A) neurons
were treated overnight in the presence of U18 and stained with
filipin. Similar to NPC1I1061T patient fibroblasts, U18 treatment
induced the accumulation of cholesterol within vesicles (Figures
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1D and 1E). While the median vesicle size of neurons cultured
without U18 (control) was 0.03 mm2 (Q1 = 0.01 mm2 and Q3 =
0.12 mm2), the median vesicle size of neurons cultured in the
presence of U18 was 0.11 mm2 (Q1 = 0.02 mm2 and Q3 =
0.49 mm2). Thus, treatment of neurons with U18 mimics the accumulation of cholesterol observed in fibroblasts from NPC1I1061T
patients and represents a pharmacological tool to dissect
the role of lysosome cholesterol efflux in regulating neuronal
function.
To test whether U18-induced cholesterol accumulation alters
neuronal excitability, action potentials (APs) were recorded in
current-clamp mode using the perforated-patch configuration.
Figure 1F shows recordings from a representative neuron
cultured in the absence of U18 (control). Here, injecting 40 pA
elicits a solitary AP despite the depolarizing stimulus being
applied for 1 s (black trace). This typical firing pattern of sympathetic neurons corresponds to the cell adapting to the stimulus
(spike adaptation) (Brown and Passmore, 2009; Zaika et al.,
2006). In striking contrast, the same stimulus induced the firing
of 9 APs in a neuron cultured in the presence of U18 (Figure 1F,
U18, black trace). We interpreted this result as a loss of spike
adaptation. From these data it is also noticeable that the neuron
cultured in the presence of U18 fired more APs per unit of injected current (e.g., 20 pA, red trace) compared to the control
neuron. To quantify changes in excitability, we measured the
following: (1) the resting membrane potential (Vrest), (2) the
amount of current injected necessary to elicit at least 1 AP
(loosely called here rheobase), and (3) the number of APs
fired with increasing current injections. Neurons cultured in
the presence of U18 had a 9 mV more depolarized Vrest (Figure 1G, control: 59 ± 2 mV, U18: 50 ± 2 mV), required less
current injection to induce AP firing (Figure 1H, control: 37 ±
5 pA, U18: 17 ± 4 pA), and fired more APs per picoampere of
current injected (Figure 1I). These U18-mediated alterations
in AP firing could also be recapitulated in cultured hippocampal
neurons (Figures S1B and S1C). In conclusion, inhibiting NPC1mediated cholesterol egress from the lysosome leads to neurons becoming more excitable.
NPC1I1061T Disease Neurons Are Hyperexcitable
Overnight application of U18 has been used extensively to investigate cellular changes in NPC1 disease. Despite its utility in doing so, this inhibition is acute relative to the chronic changes that
occur during disease development in patients. Accordingly, the
changes in electrical activity described above could represent
transient changes in excitability observed when NPC1 is
inhibited for hours; but over longer periods, neurons may adapt
to restore their excitability. Therefore, to test whether neurons
were also hyperexcitable in conditions closer to those of
patients suffering from NPC1 disease (Figure 2A), we isolated
neurons from a recently developed NPC1I1061T knockin murine
model (Praggastis et al., 2015). Figure 2B shows micrographs of
filipin-stained neurons isolated from NPC1I1061T mice compared
to littermate WT controls. Similar to patient fibroblasts and U18treated neurons, NPC1I1061T neurons exhibit an enhanced accumulation of cholesterol within vesicular structures, with the
distribution of vesicle size shifted toward larger vesicles in
NPC1I1061T neurons. While the median vesicle size in neurons
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Figure 2. NPC1I1061T Disease Neurons Are Hyperexcitable
(A) Schematic of the hypothesis: NPC1I1061T disease neurons are hyperexcitable.
(B) Inverted confocal micrographs of WT (left) and NPC1I1061T (right) mouse sympathetic neurons fixed and stained with filipin to show the accumulation of
cholesterol.
(C) Comparison of normalized cumulative frequencies of vesicle size between wild-type (WT; black, 28 cells, 1,688 vesicles) and NPC1I1061T (red, 24 cells, 1,043
vesicles, *p < 0.0005, Mann-Whitney-Wilcoxon test) neurons.
(D) Top: schematic of current injection protocol. Center: WT neuron fires 1 AP in response to 40 pA current injection (black trace). Bottom: NPC1I1061T neuron fires
several APs with 40 pA current injection (black trace, 9 APs). Dotted lines: 65 mV.
(E) Summary of Vrest measured from WT (empty circles, n = 20) or NPC1I1061T (red circles, n = 18) neurons.
(F) Histogram comparing the rheobase in WT (empty circles, n = 20) and NPC1I1061T (red circles, n = 18) neurons.
(G) Comparison of the number of APs induced with increasing current injections in WT (empty circles, n = 20) and NPC1I1061T (red circles, n = 18) neurons.

from WT mice was 0.01 mm2 (Q1 = 0.01 mm2 and Q3 = 0.08 mm2),
the median vesicle size in neurons from NPC1I1061T mice
was 0.12 mm2 (Q1 = 0.02 mm2 and Q3 = 0.34 mm2). Next, we
measured AP firing in WT and NPC1I1061T neurons. Figure 2D
contrasts the electrical responses from representative neurons
of each group. Comparable to what was observed following
NPC1 inhibition, a 40-pA current injection induced the firing of
a solitary AP in WT neurons, whereas the same injection
stimulus produced 9 APs to fire from an NPC1I1061T neuron.
Analysis of neuronal electrical properties revealed that
NPC1I1061T neurons had an 8-mV more depolarized Vrest (Figure 2E, WT: 56 ± 1 mV, n = 20; NPC1I1061T: 48 ± 2 mV),
required less current to induce AP firing (Figure 2F, WT: 29 ±
4 pA; NPC1I1061T: 14 ± 2 pA), and fired a greater number of
APs per picoampere of current injected (Figure 2G, 100 pA;
WT: 4 ± 1 AP; NPC1I1061T: 16 ± 2 APs). These results show
that the most prevalent NPC1 disease-causing mutation renders
neurons hyperexcitable, suggesting a common mechanism that
relates lysosomal cholesterol transport to the ability of neurons
to send and receive electrical inputs.

Loss of NPC1 Function Reduces KCNQ2/3 Current
(IKCNQ2/3)
Based on the significant changes in neuronal firing behavior, we
hypothesized that KCNQ2/3 voltage-gated potassium channel
(KV 7.2/7.3) current density may be altered in NPC1 disease (Figure 3A). Our rationale follows: (1) KCNQ2/3 channels activate at
negative potentials (65 mV) and thus help establish Vrest, (2)
KCNQ2/3 channels open in response to depolarization to repolarize the membrane potential, and (3) KCNQ2/3 channels participate in spike frequency adaptation (Brown and Passmore, 2009).
Thus, reduced IKCNQ2/3 is expected to depolarize Vrest increase
intrinsic electrical excitability, and decrease spike frequency
adaption—all electrophysiological consequences observed in
NPC1 disease neurons. Consequently, we measured IKCNQ2/3
densities from U18-treated, NPC1I1061T, and NPC1/ neurons.
IKCNQ2/3 density was smaller following the inhibition of NPC1 (Figures 3B and 3C, 1.8 ± 0.3 pA/pF) compared to control neurons
(5.9 ± 0.8 pA/pF). This reduction in IKCNQ2/3 density was not
observed following a 2-min acute application of the inhibitor,
ruling out a direct inhibition or block of the channel (Figure S2).

Cell Reports 27, 2636–2648, May 28, 2019 2639

A

and 3G, WT: 6.8 ± 0.8 pA/pF; NPC1/: 2.9 ± 0.4 pA/pF). Consequently, inhibition, deletion, or disease-causing mutation of the
NPC1 cholesterol transporter reduce IKCNQ2/3 density and offer
a potential mechanism underlying the hyperexcitability phenotype in NPC1 disease.
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(A) Schematic of the hypothesis: reduction in IKCNQ2/3 underlies NPC1I1061T
hyperexcitability.
(B) Comparison of IKCNQ2/3 recordings from neurons cultured overnight without
(control) or with 1 mM U18. Arrow points toward the tail current, which was
used to measure KCNQ2/3 current amplitude.
(C) Summary of IKCNQ2/3 amplitude normalized to cell size from control (n = 16)
and U18-treated (n = 11) neurons.
(D) IKCNQ2/3 recordings from neurons isolated from WT or NPC1I1061T mice.
(E) Summary of IKCNQ2/3 density from WT (n = 12) and NPC1I1061T (n = 12) neurons.
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NPC1 (NPC1/).
(G) Summary of IKCNQ2/3 density from WT (n = 11) and NPC1/ (n = 12). Dotted
lines in (B), (D), and (F): 0 pA.
See also Figure S2.

Furthermore, IKCNQ2/3 density was also smaller in neurons from
NPC1I1061T mice (Figures 3D and 3E, WT: 9.0 ± 1.0 pA/pF;
NPC1I1061T: 4.2 ± 0.8 pA/pF) and NPC1/ mice (Figures 3F
2640 Cell Reports 27, 2636–2648, May 28, 2019

Opening KCNQ2/3 Channels Rescues NPC1I1061T
Neuron Excitability
Following the premise that the reduction of IKCNQ2/3 leads to a
hyperexcited state in neurons with non-functional NPC1, we predicted that the application of retigabine, a KCNQ2/3 channel
opener (Gunthorpe et al., 2012), would make them less excitable
(Figure 4A). Bath application of 10 mM retigabine quickly and
reversibly restored the normal firing behavior of U18-treated
neurons (Figures 4B–4E), with fewer APs recorded per picoampere of current injected (100 pA; U18 treated: 19 ± 1 AP; with retigabine: 3 ± 2 APs; washout: 18 ± 1 APs; n = 8, p < 0.0001 for
U18 versus retigabine; p = 0.5 for U18 versus washout; and
p < 0.0001 for retigabine versus washout). Retigabine was also
effective at abrogating the hyperexcited state of NPC1I1061T neurons (Figure 4F, 100 pA; NPC1I1061T: 16 ± 2 APs; NPC1I1061T + retigabine: 8 ± 3). These results support the hypothesis that a
reduction in IKCNQ2/3 density is responsible for the enhanced
excitability observed in NPC1 disease neurons.
PM PtdIns(4,5)P2 Is Reduced in NPC1 Disease
We next asked what mechanism underlies the reduction in
IKCNQ2/3. First, we ruled out the possibility that KCNQ channel
abundance was altered in NPC1 disease (Figure S3). Then, we
tested the hypothesis that PtdIns(4,5)P2 is altered in NPC1 disease. PtdIns(4,5)P2 is the most abundant phosphoinositide at
the PM and is absolutely required for KCNQ2/3 channel function
(Suh and Hille, 2002; Zhang et al., 2003); hence, any reductions in
PtdIns(4,5)P2 could lead to reduced IKCNQ2/3 (Figure 5A). To
determine whether PtdIns(4,5)P2 is altered in NPC1 disease,
we took two approaches: expression of a fluorescently tagged,
genetically encoded PtdIns(4,5)P2 biosensor (yellow fluorescent
protein [YFP]-pleckstrin homology domain [PH]PLCd1) and ultrahigh pressure liquid chromatography coupled to tandem mass
spectrometry (UPLC-MS/MS). We chose these two complementary approaches because UPLC-MS/MS is extremely quantitative but does not distinguish specific PtdInsP2 regioisomers
(i.e., PtdIns(3,5)P2 versus PtdIns(4,5)P2), whereas the imaging
approach is semiquantitative but offers spatial information and
is excellent at differentiating specific regioisomers. Analysis of
healthy and NPC1I1061T patient fibroblasts transfected with
YFP-PHPLCd1 revealed a decrease in the ratio of fluorescence intensity at the PM compared to the cytoplasm (Cyt) in NPC1I1061T
patient fibroblasts (Figures 5B and 5C; WT: 4.0 ± 0.2, n = 21;
NPC1I1061T: 2.8 ± 0.2). In addition, MS showed a 50% reduction
in total PtdInsP2 in NPC1I1061T fibroblasts (Figure 5D; WT: 2.3 3
106 ± 0.6 3 105; NPC1I1061T: 1.2 3 106 ± 0.8 3 105). To further
test this hypothesis, we also measured PtdInsP2 levels from
three different brain regions (hippocampus, cortex, and cerebellum) of NPC1I1061T mice and found similar reductions in
PtdInsP2 across each region (Figures 5E–5H), with total PtdInsP2
reduced by 66% (Figure 5I; WT = 6.6 3 107 ± 0.9 3 107;
NPC1I1061T = 2.5 3 107 ± 0.7 3 107). These results indicate

that PtdIns(4,5)P2 is reduced in NPC1 disease and offers an underlying mechanism for the reduction of IKCNQ2/3 and neuron
hyperexcitability.
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Figure 4. Opening KCNQ2/3 Channels Rescues NPC1I1061T Neuron
Excitability
(A) Schematic of the hypothesis: opening KCNQ2/3 channels rescues
NPC1I1061T hyperexcitability.
(B) Top: schematic of current injection protocol. Family of voltage recordings
from a neuron treated overnight with 1 mM U18 (black trace, 7 APs).
(C) Family of voltage recordings from the same neuron as in (B), but after the
application of 10 mM retigabine (Rtg; black trace, 1 AP).
(D) Family of voltage recordings from the same neuron as in (B) and (C)
following 3 min of retigabine washout (black trace, 9 APs). Dotted lines in (B),
(C), and (D): 65 mV.
(E) Comparison of the number of APs induced with increasing current injections from neurons treated with U18 (empty circles), after retigabine
application (Rtg, black circles), and following washout (gray circles). Data from
eight cells collected from three independent experiments. At 100 pA injected
current, p < 0.0001 for U18 versus retigabine, p = 0.5 for U18 versus washout,
and p < 0.0001 for retigabine versus washout.
(F) Comparison of the number of APs fired per unit of injected current from
NPC1I1061T mouse neurons before (empty circles) and after (black circles)
retigabine application. Data from 14 cells collected from 3 independent experiments. At 100 pA, NPC1I1061T: 16 ± 2 APs; NPC1I1061T + retigabine: 8 ± 3,
p = 0.02.

Exogenous Application of PtdIns(4,5)P2 Rescues Both
IKCNQ2/3 and Excitability
Following the premise that neurons lacking functional NPC1
have less PtdIns(4,5)P2 and consequently reduced IKCNQ2/3 and
increased excitability, we next asked whether exogenous
dialysis of PtdIns(4,5)P2 would increase IKCNQ2/3 and rescue
excitability in U18-treated neurons (Figure 6A). Patch-clamp
electrophysiology was performed in whole-cell mode with
pipettes filled with a standard internal solution or a solution supplemented with 30 mM diC8-PtdIns(4,5)P2. Figure 6B shows
representative recordings of IKCNQ2/3 from control neurons
patched with or without diC8-PtdIns(4,5)P2. The addition of
diC8-PtdIns(4,5)P2 to the cell through the patch pipette did not
change the current density in control neurons (Figure 6D, without
diC8-PtdIns(4,5)P2: 10.9 ± 2.0 pA/pF; with diC8-PtdIns(4,5)P2:
7.8 ± 1.5 pA/pF). However, the addition of diC8-PtdIns(4,5)P2
significantly increased IKCNQ2/3 density in neurons cultured in
the presence of U18 (8.4 ± 1.3 pA/pF) compared to neurons
cultured in the presence of U18 alone (2.4 ± 0.9 pA/pF; Figures
6C and 6D). IKCNQ2/3 density was not statistically different between control neurons and U18-treated neurons following the
application of diC8-PtdIns(4,5)P2, suggesting that the exogenous addition of PtdIns(4,5)P2 rescues IKCNQ2/3 in neurons lacking functional NPC1. Finally, we tested whether the addition of
30 mM diC8-PtdIns(4,5)P2 rescues the excitability of neurons
with inhibited NPC1. Figure 6E shows representative currentclamp recordings of U18 neurons treated with or without diC8PtdIns(4,5)P2. Note that the addition of diC8-PtdIns(4,5)P2 to
neurons caused fewer APs to fire following a 40 pA current
injection (1 AP, black trace) compared to a neuron cultured in
the presence of U18 but patched without diC8-PtdIns(4,5)P2
(9 APs, black trace). In fact, neurons patched with diC8PtdIns(4,5)P2 fired fewer APs with every current injection tested,
reaching a maximum of 5 ± 2 APs when neurons were stimulated
with 100 pA current injection (n = 8), compared to 13 ± 3 APs
when neurons were patched without PtdIns(4,5)P2 (Figure 6F).
In conclusion, exogenous application of diC8-PtdIns(4,5)P2 to
neurons lacking functional NPC1 is enough to rescue the hyperexcitable phenotype, supporting the hypothesis that these neurons have less PtdIns(4,5)P2 and that the reduction of this lipid is
the underlying mechanism of hyperexcitability in NPC1 disease.
Upregulation of ABCA1 Reduces PtdIns(4,5)P2, Leading
to Hyperexcitability in NPC1 Disease
Finally, we sought to determine the molecular link between the
accumulation of cholesterol in the lysosome and the reduction
of PtdIns(4,5)P2 at the PM. A striking consequence of disrupting
NPC1-dependent cholesterol efflux is the activation of SREBP, a
transcription factor that controls the synthesis of cholesterol and
other membrane lipids (Brown and Goldstein, 1997). This transcription factor not only controls cholesterol synthesis through
an end product feedback mechanism but it also controls many
other physiological processes. For instance, the overexpression
of SREBP in myocytes changes the expression of 1,500 genes
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(A) Schematic of the hypothesis: decreased IKCNQ2/3 density is due to reduced PM PtdIns(4,5)P2.
(B) Top: diagram illustrating PHPLCd1 as a PtdIns(4,5)P2 biosensor. Bottom: inverted confocal micrographs of healthy (left) and NPC1I1061T (right) patient fibroblasts
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See also Figure S3.

2642 Cell Reports 27, 2636–2648, May 28, 2019

Figure 6. Exogenous Application of PtdIns(4,5)P2 Rescues Both
IKCNQ2/3 and Excitability
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Inset: protocol used to isolate IKCNQ2/3. Dotted line: 0 pA.
(C) Comparison of IKCNQ2/3 recordings from neurons cultured overnight with
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(D) Summary of IKCNQ2/3 amplitude normalized to cell size from control (n = 8,
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(E) Top: schematic of current injection protocol. Center: family of voltage
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(F) Comparison of the number of APs induced with increasing current injections in U18-treated neurons (red, n = 6) and U18-treated neurons patched
with diC8-PtdIns(4,5)P2 (pink, n = 8).

p = 0.003
p = 0.2

p = 0.002

IKCNQ2/3 density
(pA/pF)

20

10

0
Control Control U18
+
PIP2
F

Inhibition of NPC1

Inhibition of NPC1

U18

-40 pA

# Action Potentials

ΔI = 10 pA

PIP2

E

15

U18

10
PIP2

5
0

100 mV
500 ms

U18
+
PIP2

0

20 40 60 80 100
Current (pA)

(Rome et al., 2008). Considering the significant number of protein-coding genes under the control of SREBP, we tested
whether crucial enzymes related to PtdIns(4,5)P2 metabolism
are altered in NPC1 disease (Figure 7A). To begin, we verified
that the activation of SREBP, independent of NPC1 function,
reduced PM PtdIns(4,5)P2 (Figure S4). Next, determination of
the protein abundances of PIP5K1A (phosphatidylinositol
4-phosphate 5-kinase type 1A), SYNJ1 (Synaptojanin 1), and
PLCb1 (phospholipase C b1) revealed no significant difference
between healthy and NPC1I1061T (Figures 7B and 7C). Therefore,
we ruled out the misregulation of any of these three important proteins as a possible mechanism for the reduction of
PtdIns(4,5)P2 in NPC1 disease.
Given that phosphoinositide lipid kinases or lipid phosphatases do not appear to underlie the reduction in PM PtdIns(4,5)
P2, we focused our attention on proteins that are key regulators
of the transport of both cholesterol and phosphoinositide metabolism. To this end, we tested whether several known phosphoinositide transfer proteins (ORP2, ORPL1, ORP5/8) or the ABCA1
(ATP-binding cassette transporter-A1) transporter are differentially expressed in NPC1 disease. Oxysterol-binding protein
(OSBP)-related proteins are transfer proteins that transfer
cholesterol at membrane contact sites through the countertransport of PtdIns4P and PtdIns(4,5)P2 (Ghai et al., 2017;
Mesmin et al., 2013; Wang et al., 2019; Zhao and Ridgway,
2017), whereas ABCA1 (ATP-binding cassette transporter-A1)
is a transmembrane protein, which plays a major role in lipid homeostasis by regulating cholesterol efflux from the cell. In addition, ABCA1 has been recently reported to exhibit PtdIns(4,5)P2
floppase activity, moving PtdIns(4,5)P2 from the inner leaflet to
the outer leaflet of the PM to mediate Apo1-dependent binding
during nascent high-density lipoprotein (HDL) assembly (Gulshan et al., 2016). Determination of protein abundances revealed
that the average fold change of ORP2 was 1.35 ± 0.05 (n = 3, p =
0.0004), ORPL1 was 1.33 ± 0.06 (n = 4, p = 0.002), ORP8 was
1.16 ± 0.25 (n = 4, p = 0.5), and ABCA1 was 3.3 ± 0.3 (n = 4,
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p = 0.002) in NPC1I1061T fibroblasts (Figures 7I and S5). Thus, in
NPC1 disease, several key phosphoinositide transfer proteins
are differentially expressed. The fold change of OPR2 and
ORPL1 is small compared to the >3-fold increase in ABCA1
abundance; therefore, we focused our attention on determining
whether ABCA1 is responsible for reducing PtdIns(4,5)P2,
PtdIns(4,5)P2-dependent ion channel current, and excitability in
NPC1 disease.
To test for the involvement of ABCA1 in altering PtdIns(4,5)
P2, we took two complementary approaches that, independently of NPC1 function, increase the abundance of ABCA1.
First, we treated healthy patient fibroblasts or neurons with an
agonist of the nuclear liver factor receptor (LXR) T0901317 (Figures 7E, 7F, and S6), which upregulates the expression of
ABCA1. Second, we used a cell line that stably expresses the
ABCA1 transporter at a high copy number (Figures 7G and
7H). Under both experimental conditions, there was a lower
PM-to-Cyt fluorescence intensity ratio of the PtdIns(4,5)P2
biosensor (PHPLCd1), suggesting reduced PtdIns(4,5)P2. Next,
we tested the hypothesis that blocking ABCA1 rescues both
IKCNQ2/3 and excitability in NPC1 disease (Figure 7J). To block
ABCA1, we added 10 mM probucol to neurons that were isolated from NPC1I1061T mice. Blocking ABCA1 increased
IKCNQ2/3 density in NPC1I1061T neurons from 1.8 ± 0.5 to 6.4 ±
1.1 pA/pF (Figure 7K, p = 0.005). Moreover, neurons from
NPC1I1061T mice treated with probucol fired 6.5 ± 1.7 APs
with 100 pA current injection and exhibited more spike adaptation (Figure 7L, n = 9), meaning that they were less excitable
than neurons from NPC1I1061T mice (compare data from Figure 2G). Finally, treating U18 neurons with small interfering
RNA (siRNA) directed against ABCA1 increased IKCNQ2/3 current density, restored the resting membrane potential, and
rescued excitability (Figure S7). These data suggest that the
loss of NPC1 function indirectly alters the level of proteins
that transport both cholesterol and PtdIns(4,5)P2, leading to
decreased PM PtdIns(4,5)P2, decreased IKCNQ2/3, and, consequently, enhanced excitability.

DISCUSSION
Here, we show for the first time that both inhibition and diseasecausing mutation of the lysosomal cholesterol transporter,
NPC1, render neurons hyperexcitable, in that neurons have a
more depolarized Vrest, less current is required to induce them
to fire APs, and they lose the ability to complete spike adaptation. Changes in excitability result from reduced PM PtdIns(4,5)
P2 and the subsequent reduction of KCNQ2/3 channel function.
Furthermore, the molecular mechanism that links cholesterol
accumulation and PtdIns(4,5)P2 reduction is the upregulation
of ABCA1. Based on these data, we propose that NPC1 disease
is a phosphoinositide-deficient disease and that ABCA1 links
lysosomal cholesterol efflux with PM phosphoinositide levels to
tune neuronal excitability.
PtdIns(4,5)P2 Deficiency Underlies Neuronal
Hyperexcitability in NPC1 Disease
Like many monogenetic disorders, despite the seemingly nondescript nature of a single mutation, the mechanisms of NPC1 pathogenesis are complicated. For NPC1 disease, >1,500 genes
(Rome et al., 2008) and 300 proteins (Rauniyar et al., 2015)
are differentially regulated. At the cellular level, these alterations
manifest as defects in vesicular trafficking, mTOR signaling (Castellano et al., 2017), lysosomal calcium handling (Lloyd-Evans
et al., 2008), and lipid localization (Lloyd-Evans et al., 2008; Praggastis et al., 2015). We report for the first time hyperexcitability in
NPC1 disease. Evidence presented in this study suggests that
the mechanism underlying this enhanced excitability is a reduction in IKCNQ2/3 mediated by a decline in PtdIns(4,5)P2. Could
other lipids altered in NPC1 disease, such as cholesterol or
sphingolipids, account for the reduction in IKCNQ2/3? For cholesterol, KCNQ2/3 channels are reported as being negatively
regulated by PM cholesterol (Lee et al., 2010). In cells lacking
functional NPC1, there is a described reduction in the amount
of cholesterol in the endofacial leaflet of the PM (Maekawa and
Fairn, 2015). Thus, decreased PM cholesterol in NPC1 disease

Figure 7. Upregulation of ABCA1 in NPC1 Disease Decreases PtdIns(4,5)P2 and Leads to Hyperexcitability
(A) Schematic of PtdIns(4,5)P2 synthesis. Relevant enzymes are in red.
(B) Blot stained for PtdIns(4,5)P2 metabolizing enzymes PIP5K1A, SYNJ1, and PLCb1 from cerebellums collected from NPC1I1061T and WT littermate mice.
(C) Summary of fold change of protein abundance in NPC1I1061T cerebellum relative to WT (n = 4 blots from different mice).
(D) Schematic of hypothesis: upregulation of ABCA1 reduces PtdIns(4,5)P2 levels.
(E) Confocal micrographs of healthy (left) and NPC1I1061T (right) fibroblasts transfected with PHPLCd1. Some healthy fibroblasts were treated with 1 mM T0901317,
an LXR agonist, overnight (center). Insets show the reduced intensity of PHPLCd1 at the PM from healthy fibroblasts treated with LXR agonist.
(F) Comparison of the ratio of PHPLCd1 fluorescence intensity at the PM relative to the Cyt in healthy (empty, n = 13), healthy treated with LXR agonist (yellow,
n = 15), and NPC1I1061T fibroblasts (red, n = 10).
(G) Inverted confocal micrographs of HeLa cells with endogenous levels of ABCA1 (WT, left) and overexpressed levels of ABCA1 (ABCA1, right) transfected with
PHPLCd1. Insets show the reduced intensity of PHPLCd1 at the PM of HeLa cells with upregulated levels of ABCA1.
(H) Comparison of the ratio of PHPLCd1 fluorescence intensity at the PM to the Cyt in WT (n = 40) and ABCA1 HeLa cells (n = 33).
(I) Top: blot stained for ABCA1 from cerebellum collected from NPC1I1061T and WT littermate mice. Bottom: summary of fold change of ABCA1 abundance in
NPC1I1061T cerebellum relative to WT (n = 4 blots from different mice).
(J) Schematic of the hypothesis: inhibition of ABCA1 in NPC neurons rescues current density and excitability.
(K) Inset: protocol used to isolate KCNQ2/3 current. Comparison of KCNQ2/3 current recordings from neurons isolated from WT (black) and NPC1I1061T (red)
mice. Some neurons isolated from NPC1I1061T were treated with 10 mM probucol (pink). Dotted line: 0 pA. Bottom: summary of KCNQ2/3 current density from WT
(n = 8, empty), NPC1I1061T (n = 6, red), and NPC1I1061T treated with probucol (n = 8, pink).
(L) Top: schematic of current injection protocol. Center: family of voltage recordings shows a probucol-treated NPC1I1061T neuron firing 2 APs with 40 pA current
injection (black trace). Dotted line: 65 mV. Bottom: comparison of the number of APs induced with increasing current injections in probucol-treated NPC1I1061T
neurons (pink, n = 9) and WT and NPC1I1061T neurons (same data as Figure 2).
See also Figures S4, S5, S6, and S7.
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would disinhibit KCNQ2/3 channels and result in more current,
which is the opposite of our observations. Another lipid that
accumulates in lysosomes in NPC1 disease is sphingosine-1phosphate (S1P) (Praggastis et al., 2015). Some reports show
that KCNQ2/3 channel activity can be weakly stimulated (increase in channel open probability [Po] to 0.16) by a high concentration (100 mM) of S1P (Telezhkin et al., 2012). In contrast, a
lower concentration (10 mM) of PtdIns(4,5)P2 is enough to activate KCNQ2/3 channels with a Po of 0.54. Therefore, if S1P is
reduced in the PM of NPC1 disease neurons, it would be anticipated that the differences in affinity that KCNQ2/3 has for each
lipid would mean that any S1P effects would be secondary to
PtdIns(4,5)P2-dependent alterations. In conclusion, decreases
in either cholesterol or S1P appear unlikely to account for the
reductions of IKCNQ2/3 in NPC1 disease.

neuropathology (Berridge, 2010), we hypothesize that alterations in the excitability alluded to above would facilitate
enhanced Ca2+ influx into cerebellar neurons, potentially leading
to their degeneration in NPC1 disease. Future experiments are
needed to establish causation between hyperexcitability and
cell death in NPC1 disease.
To conclude, mutations within the NPC1 protein lead to a
poorly understood sequence of events that end in neurodegeneration and premature death. We have defined steps in
the pathogenic cascade of NPC1 disease, namely upregulation of ABCA1 leading to a decrease in PM PtdIns(4,5)P2
and IKCNQ2/3, which produces hyperexcitability in neurons.
Thus, NPC1 disease is not only a cholesterol storage disease
but also a phosphoinositide-deficient disorder with a hyperexcitability phenotype.

Cholesterol and PtdIns(4,5)P2 Dysregulation in
Neurodegenerative Diseases
We present evidence linking the disruption of lysosomal cholesterol efflux with decreases in PtdIns(4,5)P2-dependent KCNQ2/3
channel activity, leading to aberrant neuronal activity. At the
molecular level, our data suggest that the cholesterol transporter
and PtdIns(4,5)P2 floppase, ABCA1, is responsible for the
decline in PtdIns(4,5)P2 that consequently modifies the electrical properties of NPC1 disease neurons. Fibroblasts from patients with Tangier disease, a disease caused by mutations in
ABCA1, transfer 50% less PtdIns than fibroblasts from healthy
patients (von Eckardstein et al., 1998), while mutations in
ABCA1 have been associated with a higher risk of Alzheimer
disease (Nordestgaard et al., 2015). Thus, there is a precedent
for the involvement of ABCA1 as a potential contributing factor
in neurodegeneration. Is there evidence in the literature to
suggest that other neurodegenerative diseases have either
dysfunction of KCNQ2/3 channel activity or altered levels of
PtdIns(4,5)P2? In fact, there is accumulating evidence that mutations in the genes encoding KCNQ2/3 subunits or PtdIns(4,5)P2metabolizing enzymes lead to neuropathies similar to those in
NPC1 disease. Mutations in KCNQ2/3 cause the hyperexcitability of neurons, leading to epileptic phenotypes in neonatal
epilepsy (Jentsch, 2000; Watanabe et al., 2000), Huntington disease (Cao et al., 2015), and the bulbar form of amyotrophic
lateral sclerosis (ALS) (Ghezzi et al., 2018). Opening KCNQ2/3
channels with retigabine protects motoneurons against the
excitotoxicity characteristic of this form of ALS (Ghezzi et al.,
2018). Further, mutations in the enzymes responsible for
PtdIns(4,5)P2 synthesis are associated with Alzheimer disease
(Zhu et al., 2015), Parkinson disease (Cao et al., 2017), and Friedreich ataxia (Bayot et al., 2013), another rare neurodegenerative disease. These data support the idea that maintaining
PtdIns(4,5)P2 levels in neurons is essential for normal brain function and that dysfunction of KCNQ2/3 channel activity may be a
contributing factor to the progression of neurodegenerative diseases. It is important to note that the relationship between
enhanced neuronal excitability and neurodegeneration in
NPC1 disease is correlative at this point. Given the fundamental
importance of regulated ion channel function and Ca2+ homeostasis for neuron health and the Ca2+ hypothesis of neurodegeneration, which posits that altered Ca2+ dynamics contribute to
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Murine models of NPC1 disease
NPC1 knock-out (NPC/, RRID: IMSR_JAX:003092), NPC1I1061T knock-in (Praggastis et al., 2015), and wild-type (WT) mice from a
C57BL/6 background were kindly provided by Daniel Ory (Washington University Saint Louis). Male C57BL/6 WT mice used for experiments involving U18666A (U18, SIGMA, Cat # 662015) were purchased from the Jackson Laboratory (RRID: IMSR_JAX:000664).
All animals were kept in an animal facility with controlled conditions and were given standard chow and water ad libitum. The animal
handling protocol was approved by the University of California Institutional Animal Care and Use Committee. To genotype NPC1I1061T
mice, we extracted DNA and amplified an NPC1 allele with the following primers: forward (50 -tgatctgcacacttggaaccgag-30 ) and
reverse (50 -cactgccttgagcagcatctcag-30 ). WT allele was identified by a 200 bp fragment, whereas the knock-in allele was identified
by a 234 bp fragment. Heterozygous mice, containing both 200 bp and 234 bp, were not used in this study. Experiments using either
knock-out or knock-in animals were conducted using both males and females. Knock-out animals were used at around 70 days old.
Knock-in animals were used at around 90 days old.
Cell lines
Fibroblast cell lines from a healthy male (GM05659, RRID: CVCL_7434) and a male patient with a homozygous mutation in NPC1I1061T
(GM18453, RRID: CVCL_DA78, from the NIGMS repository) were purchased from the Coriell Institute. Fibroblasts were grown in
Eagle’s Minimum Essential Medium (MEM) with Earle’s salts and non-essential amino acids (SIGMA, Cat # M5650) supplemented
with 2 mM L-glutamine (GIBCO, Cat # 25030-081), 15% non-inactivated fetal bovine serum (GIBCO, Cat # 26140-079) and 0.2%
penicillin/streptomycin (GIBCO, Cat # 15140-122), passaged twice a week, and incubated in 5% CO2 at 37 C.
HeLa cells stably expressing ABCA1-GFP were provided by Dr. Alan Remaley, NHLBI, Bethesda, MD. HeLa cells were grown in
DMEM (GIBCO, Cat # 11995-065) supplemented with 10% non-inactivated fetal bovine serum and 0.2% penicillin/streptomycin,
passaged twice a week, and incubated in 5% CO2 at 37 C. Expression of ABCA1-GFP HeLa cells was induced by adding
150 mg/ml geneticin (GIBCO, Cat # 10131-035) and 200 mg/ml Hygromycin (Invitrogen, Cat # 10687010).
METHOD DETAILS
Neuron isolation
Neurons from superior cervical ganglion (SCG) were prepared from 10 to 16 week-old female or male mice by enzymatic digestion
following a standardized protocol for rats (Vivas et al., 2013) but reducing the amount of enzymes. Briefly, mice were anesthetized
with pentobarbital sodium (VETONE, Cat # 501016) before extraction of the SCG. SCG were cleaned and sliced into 4 pieces. This
tissue was transferred to a tube containing 10 U/ml papain (SIGMA, Cat # 4762) in Hank’s solution and kept at 37 C for 6 min, then it
was transferred to a solution containing 0.33 mg/ml collagenase type II (Worthington, Cat # LS004176) and 2.5 mg/ml dispase
(GIBCO, Cat # 0479) for up to 60 min. Every 20 min the tissue was pipetted to dissociated into individual cells. After obtaining a
homogeneous cell suspension, cells were washed with DMEM followed by centrifugation at 180 g for 3 min. Washing step was
repeated 3 times. Isolated neurons were plated on poly-L-lysine (MW > 300,000, SIGMA, Cat # P5899) coated glass coverslips
and incubated in 5% CO2 at 37 C in DMEM supplemented with 10% FBS and 0.2% penicillin/streptomycin. Neurons were used
up to 24 h after plating.
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Filipin Staining and Super-resolution Imaging
Cells washed with PBS were fixed with a mix of 3% paraformaldehyde (Electron Microscopy Sciences, Cat # 15710) and 0.1% glutaraldehyde (SIGMA, Cat # G7651) for 10 min at 21 C. Following a 5-minute incubation with sodium borohydrate (10 mM, SIGMA, Cat #,
213462), cells were stained with 3 mg/ml filipin (SIGMA, Cat # F9765) for 2 h at room temperature. Cells were imaged in PBS. During
the filipin staining process cells were protected from unnecessary light exposure. Cells were imaged using a Zeiss880 AiryScan microscope (axial resolution of 120 nm) by exciting with a 405 nm LED. This imaging mode allowed us to resolve cholesterol-containing
vesicles.
Electrophysiological Recordings
All electrophysiological recordings were performed at room temperature. Voltage responses were recorded using perforated-patch
configuration (except Figure 6) in the current-clamp mode, whereas KCNQ2/3 current was recorded using the whole-cell configuration in voltage clamp mode. To isolate KCNQ2/3 tail currents, the voltage was held at 20 mV, before stepping to 60 mV. The
amplitude of KCNQ2/3 currents was measured from the resulting currents relative to the current at the end of the pulse (current close
to 0 pA). We used an Axopatch 200B amplifier coupled with an Axon Digidata 1550B data acquisition board (Molecular Devices
Electrophysiology) to acquire the electrical signals. Patch pipettes had a resistance of 2 – 6 MU. Liquid junction potential of 4 mV
was calculated using the pCLAMP 10 software and was not corrected for, hence the Vrest reported in the Results section is in fact
4 mV more negative (around 63 mV in WT SCG neurons). Voltage responses were sampled at 5 KHz, whereas currents were
sampled at 2 KHz. For current recordings, cell capacitance was cancelled out and series resistances of < 10 MU were compensated
by 60%. Due to remaining series resistance, voltage error is expected to be < 4 mV. The bath solution (Ringer’s solution) contained
150 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 8 mM glucose, adjusted to pH 7.4 with NaOH. The internal
solution used to fill the patch pipettes contained 175 mM KCl, 1 mM MgCl2, 5 mM HEPES, 0.1 mM K4BAPTA, 3 mM Na2ATP, and
0.1 mM Na3GTP, adjusted to pH 7.2 with KOH. For current-clamp recordings, 30 mM amphotericin B (SIGMA, Cat # A4888) was
added to the internal solution to facilitate electrical access to the cell. The bath solution was perfused at 2 ml/minute, permitting solution exchange surrounding the recording cell with a time constant of 4 s. DiC8-PtdIns(4,5)P2 (30 mM, Avanti Polar Lipids, Cat #
850185) was added in the internal solution.
Protein extraction and abundance determination
Protein from cell cultures, SCG, or brain tissue was harvested in RIPA buffer (Thermo Scientific, Cat # 89900) with Complete, Mini,
EDTA-free protease inhibitor cocktail (Roche, Cat # 11836170001) for 15 min at 4 C. For SCG and brain tissue, protein samples were
sonicated using a bath sonicator at 4 C. Postnuclear supernatant was isolated by centrifuging for 20 minutes at 13,600 g at 4 C.
Protein concentration was quantified with a plate reader using the Pierce BCA protein assay kit (Thermo Scientific, Cat # 23225).
Protein samples were resolved in 4%–12% Bis-Tris gels under reducing conditions. Proteins were transferred onto nitrocellulose
membranes (Life Technologies, Cat # LC2000) using the Mini-Bolt system (Thermo Scientific, Cat # A25977). Membranes were
blotted using rabbit monoclonal anti-NPC1 (Abcam, Cat # ab134113, RRID: AB_2734695, 1:1,000), rabbit anti-KCNQ2 (Abcam,
Cat # ab22897, RRID: AB_775890, 1:500), mouse anti-ABCA1 (Abcam, Cat # ab18180, RRID: AB_444302, 1:1000), rabbit
anti-PIP5K1A (Cell Signaling Technology, Cat # 9693, RRID: AB_2164698, 1:500), rabbit anti-SYNJ1 (SIGMA, Cat # HPA011916,
RRID: AB_1857692, 1:500), rabbit anti-PLCb1 (Abcam, Cat # ab182359, 1:1000), and mouse anti-b-actin (Thermo Scientific, Cat #
MA1-91399, RRID: AB_2273656, 1:10,000). Blotted bands were detected using fluorescent secondary antibodies goat anti-rabbit
680RD (P/N 926-68071, LI_COR biosciences, RRID: AB_10956389, 1:10,000) and goat anti-mouse 800CW (P/N 925-32210, LI_COR
biosciences, RRID: AB_2687825, 1:20,000). ImageJ was used to calculate fluorescence density of each band. The abundance of
NPC1 or KCNQ2 from NPC1I1061T or U18-treated tissue was reported as normalized to b-actin and relative to the abundance in
WT or control tissue.
Measuring PtdIns(4,5)P2
To measure PtdIns(4,5)P2 in fibroblasts, a plasmid for PHPLCd1 tagged with YFP was transfected (0.2 mg DNA) using Lipofectamine
LTX (Invitrogen, Cat # 11668-027). Imaging of this biosensor was performed 24 h post-transfection using a spinning disk
confocal microscope (Andor W-1 spinning disk). To measure PtdIns(4,5)P2 from fibroblasts and brain samples by mass spectrometry, lipids were extracted with butanol and chloroform, as described previously (Traynor-Kaplan et al., 2017). A PtdIns(4,5)P2
standard was added 17:0, 20:4 PtdIns(4,5)P2 (Avanti Lipids, Cat # LM-1904) to all biological samples. Samples were neutralized
by methylation and infused with sodium formate and analyzed using a Waters XEVO TQ-S MS/MS in multiple reaction monitoring
mode (MRM) using electrospray and positive ion mode. Elution profiles plotting the intensity (arbitrary units) as a function of
elution time (minutes) were analyzed to determine relative changes in PtdInsP2 levels between samples. Total integrated areas
under peaks from samples and standards were quantified using MassLynx software (Waters, RRID: SCR_014271). Peak areas
of PIP2 from the biological sample were normalized to the synthetic standard and further corrected for tissue amount using total
protein.
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QUANTIFICATION AND STATISTICAL ANALYSIS
We used IGOR Pro (IGOR Software, WaveMetrics, RRID: SCR_000325), Excel (Microsoft), and Prism (GraphPad, RRID:
SCR_002798) to analyze data. ImageJ (RRID: SCR_003070) was used to process images. Data were collected from independent
experiments from at least three mice and are presented as Mean ± SEM. For the super-resolution data of vesicle size, the median,
first (Q1), and third (Q3) quartiles instead of the mean was used given that the data were not normally distributed (Normality test in
Prism). A non-parametric statistical test (Mann-Whitney Wilcoxon) was used to test for statistical significance between vesicle size in
different conditions. All other statistical analyses presented in this study were performed using parametric Student’s t test, considering p values < 0.05 as statistical significance. The number of cells used for each experiment is detailed in each figure legend.
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Figure S1. Inhibition of NPC1 increases hippocampal neuron excitability. Related to
Figure 1. A. Inverted confocal micrographs of control (left) and U18-treated (right) hippocampal
neurons fixed and stained with filipin. Insets highlight accumulation of filipin within vesicle
structures. B. Current-clamp recordings of spontaneous firing from control (left) and U18-treated
(right) hippocampal neurons. C. Quantification of spontaneous action potential (AP) firing
frequency. Note that U18-treated neurons fire APs more frequently.

Figure S2. U18 does not inhibit IKCNQ2/3 acutely. Related to Figure 3. A. Representative IKCNQ2/3
current recordings before (left, black trace) and 2 min after (right, red trace) U18 application. Inset
shows the protocol used to isolate IKCNQ2/3. B. Time course of normalized IKCNQ2/3 amplitude. Purple
bar indicates the time of application of U18 (1 μM).

Figure S3. Inhibition or mutation of NPC1 does not alter KCNQ channel abundance. Related
to Figure 5. A. Schematic of the hypothesis: there are fewer KCNQ2/3 channels in neurons with
non-functional NPC1. B. Inverted confocal micrographs of neurons fixed and stained with filipin
show accumulation of cholesterol in neurons isolated from ganglia cultured overnight with 1 μM
U18. C. Comparison of normalized cumulative frequencies of vesicle size between control (black,
18 cells, 1015 vesicles) and U18-treated neurons (red, 30 cells, 1185 vesicles, * = p < 0.0005,
Mann-Whitney Wilcoxon test). D. Blot stained for KCNQ2 and β-actin from ganglia treated without
or with U18. E. Summary of KCNQ2 abundance in neurons treated with U18 relative to control (n
= 3 biological replicates, each biological replicate from four to six ganglia, p = 0.7). F. Blots stained
for NPC1, KCNQ2, and β-actin from brain tissue collected from NPC1I1061T and WT littermate
mice. Three brain regions were analyzed separately (Cx = cortex, Hp = hippocampus, Cb =
cerebellum). G. Summary of NPC1 and KCNQ2 abundance in neurons from NPC1I1061T mice
relative to WT (n = 4 biological replicates).

Figure S4. Overexpressing SREBP decreases PM PtdIns(4,5)P2 independently of NPC1
function. Related to Figure 7. A. Control tsA-201 cell transfected with PHPLCδ1. B. Same as A,
only with SREBP also overexpressed. C. Line scans taken from the yellow lines in A and B. D.
Quantification of PHPLCδ1 ratio from control and SREBP expressing tsA-201 cells. Note that
smaller PHPLCδ1 ratio suggests less PtdIns(4,5)P2 in cells overexpressing SREBP.

Figure S5. Mutation of NPC1 mildly upregulates some lipid transfer proteins. Related to
Figure 7. A. Blots stained for ORP2, ORPL1, and ORP8 from healthy and NPC1I1061T fibroblasts.
B. Summary of fold change of protein abundance in NPC1I1061T relative to healthy fibroblasts.
Average fold change of ORP2 is 1.35 ± 0.05, n = 3, p = 0.0004. Average fold change of ORPL1
is 1.33 ± 0.06, n = 4, p = 0.002. Average fold change of ORP8 is 1.16 ± 0.25, n = 4, p = 0.5. N
number represents different cell cultures.

Figure S6. Activating LXR in hippocampal neurons decreases PM PtdIns(4,5)P2
independently of NPC1 function. Related to Figure 7. A. Left: wild-type hippocampal neuron
transfected with PHPLCδ1. Right: magnified image from white ROI in A. B. Same as A, only treated
with LXR agonist, T0901317 (500 nM) overnight. C. Line scans taken from the yellow lines in A
and B. D. Quantification of PHPLCδ1 ratio from control and LXR-treated neurons. Note that smaller
PHPLCδ1 ratio suggests less PtdIns(4,5)P2 in hippocampal neurons treated with LXR agonist.

Figure S7. ABCA1 siRNA rescues hyperexcitability phenotype from UA-treated neurons.
Related to Figure 7. A. Quantification of resting membrane potential from UA-treated (left), UAtreated neurons transfected with siRNA against ABCA1 (middle), and neurons transfected with
siRNA against ABCA1 (right). Note that knocking down ABCA1 significantly hyperpolarizes the
RMP of neurons. B. Representative examples of spontaneous firing from hippocampal neurons.
C. Comparison of IKCNQ2/3 density from tsA-201 cells transiently transfected with KCNQ2/3
channels and cultured without U18 (left), with U18 (middle), and with UA and transfected with
siRNA against ABCA1 (right). Note that knocking down ABCA1 increases KCNQ2/3 current
density to control levels. D. Representative recordings of IKCNQ2/3 from tsA-201 cells. Dotted lines
represent 0 pA current.

